We claim:

1. A compound of the formula (I)



wherein

R_1 is H;

R_2 is H, C_1-C_4alkyl which is unsubstituted or substituted by one or more substituents selected from halogen, -OH, -SH, -OCH_3, -SCH_3, -CN, -SCN and nitro;

R_3 is H, -CF_3, -C_2F_5, $-CH_2$-Z or R_2 and R_3 together form with the nitrogen form a C_3-C_6heteroaliphatic ring;

Z is H, –OH, F, Cl, $-CH_3$; -CF_3, -CH_2Cl, -CH_2F or -CH_2OH;

R_4 is C_1-C_{16} straight chain alkyl, C_3-C_{10} branched chain alkyl, -$(CH_2)_{0-6}$-C_3-C_7-cycloalkyl, -$(CH_2)_{1-6}$-Z_1, -$(CH_2)_{0-6}$-phenyl, and -$(CH_2)_{0-6}$-het, wherein the alkyl, cycloalkyl and phenyl substituents are unsubstituted or substituted;

Z_1 is –N(R_9)-C(O)-C_1-C_{10}alkyl, –N(R_9)-C(O)-$(CH_2)_{1-6}$-C_3-C_7-cycloalkyl, –N(R_9)-C(O)-$(CH_2)_{0-6}$-phenyl, –N(R_9)-C(O)-$(CH_2)_{1-6}$-het, -C(O)-N(R_{10})(R_{11}), -C(O)-O-C_1-C_{10}alkyl, -C(O)-O-$(CH_2)_{1-6}$-C_3-C_7-cycloalkyl, -C(O)-O-$(CH_2)_{0-6}$-phenyl, -C(O)-O-$(CH_2)_{1-6}$-het, -O-C(O)-C_1-C_{10}alkyl, -O-C(O)-$(CH_2)_{1-6}$-C_3-C_7-cycloalkyl, -O-C(O)-$(CH_2)_{0-6}$-phenyl, -O-C(O)-$(CH_2)_{1-6}$-het, wherein the alkyl, cycloalkyl and phenyl substituents are unsubstituted or substituted;

het is a 5-7 membered heterocyclic ring containing 1, 2 or 3 heteroatoms selected from N, O and S, or an 8-12 membered fused ring system including at least one 5-7 membered heterocyclic ring containing 1, 2 or 3 heteroatoms selected from N, O, and S, which heterocyclic ring or fused ring system is unsubstituted or substituted on a carbon atom by halogen, hydroxy, C_1-C_4alkyl, C_1-C_4 alkoxy, nitro, -O-C(O)-C_1-C_4alkyl or –C(O)-O-C_1-C_4-alkyl or on a nitrogen by C_1-C_4 alkyl, -O-C(O)-C_1-C_4alkyl or –C(O)-O-C_1-C_4-alkyl;

R_9 is H, $-CH_3$, $-CF_3$, $-CH_2OH$ or CH_2Cl;
R_{10} and R_{11} are each independently H, C_1-C_4alkyl, C_3-C_7-cycloalkyl, $-(CH_2)_{1-6}$-C_3-C_7-cycloalkyl, $-(CH_2)_{0-6}$-phenyl, wherein the alkyl, cycloalkyl and phenyl substituents are unsubstituted or substituted, or R_{10} and R_{11} together with the nitrogen are het;
X is CH or N;
R_5 is H, C_1-C_{10}-alkyl, C_3-C_7-cycloalkyl, $-(CH_2)_{1-6}$-C_3-C_7-cycloalkyl, $-C_1$-C_{10}-alkyl-aryl, $-(CH_2)_{0-6}$-C_3-C_7-cycloalkyl-$(CH_2)_{0-6}$-phenyl, $-(CH_2)_{0-4}CH-((CH_2)_{1-4}$-phenyl$)_2$, $-(CH_2)_{0-6}$-CH(phenyl)$_2$, -C(O)-C_1-C_{10}alkyl, -C(O)-$(CH_2)_{1-6}$-C_3-C_7-cycloalkyl, -C(O)-$(CH_2)_{0-6}$-phenyl, $-(CH_2)_{1-6}$-het , -C(O)-$(CH_2)_{1-6}$-het, wherein the alkyl, cycloalkyl, phenyl and aryl substituents are unsubstituted or substituted;
R_6 is H, methyl, ethyl, $-CF_3$, $-CH_2OH$ or $-CH_2Cl$; or
R_5 and R_6 together with the nitrogen are het;
R_7 and R_8 are cis relative to the acyl substituent at the one position of the ring and are each independently H, $-C_1$-C_{10} alkyl, -OH, -O-C_1-C_{10}-alkyl, $-(CH_2)_{0-6}$-C_3-C_7-cycloalkyl, -O-$(CH_2)_{0-6}$-aryl, phenyl, $-(CH_2)_{1-6}$-het, -O-$(CH_2)_{1-6}$-het, $-N(R_{12})(R_{13})$, $-S-R_{12}$, $-S(O)-R_{12}$, $-S(O)_2-R_{12}$, $-S(O)_2-NR_{12}R_{13}$ wherein the alkyl, cycloalkyl and aryl substituents are unsubstituted or substituted;
R_{12} and R_{13} are independently H, C_1-C_{10} alkyl, $-(CH_2)_{0-6}$-C_3-C_7-cycloalkyl, $-(CH_2)_{0-6}-(CH)_{0-1}(aryl)_{1-2}$, -C(O)-$C_1$-$C_{10}$alkyl, -C(O)-$(CH_2)_{1-6}$-$C_3$-$C_7$-cycloalkyl, -C(O)-O-$(CH_2)_{0-6}$-aryl, -C(O)-$(CH_2)_{0-6}$-O-fluorenyl, -C(O)-NH-$(CH_2)_{0-6}$-aryl, -C(O)-$(CH_2)_{0-6}$-aryl, -C(O)-$(CH_2)_{1-6}$-het, wherein the alkyl, cycloalkyl and aryl substituents are unsubstituted or substituted;or a substituent that facilitates transport of the molecule across a cell membrane, or R_{12} and R_{13} together with the nitrogen are het;
aryl is phenyl or naphthyl which is unsubstituted or substituted;
n is 0, 1 or 2;
and wherein
substituted alkyl substitutents are substituted by one or more substituents selected from a double bond, halogen, OH, -O-C_1-C_8alkyl, -S-C_1-C_8alkyl and $-CF_3$;
substituted cycloalkyl substitutents are substituted by one or more substituents selected from a double bond, C_1-C_8alkyl, halogen, OH, -O-C_1-C_8alkyl, -S-C_1-C_8alkyl and $-CF_3$; and

substituted phenyl or aryl are substituted by one or more substituents selected from halogen, hydroxy, C_1-C_4 alkyl, C_1-C_4 alkoxy, nitro, -CN, -O-C(O)-C_1-C_4alkyl and –C(O)-O-C_1-C_4-alkyl, or a pharmaceutically acceptable salt thereof.

2. A compound of claim 1 wherein R_2 is H or methyl and R_3 is methyl.

3. A compound of claim 1 wherein n is 1.

4. A compound of claim 1 having the stereochemistry indicated in formula II



(II)

5. A compound of claim 4 wherein R_2 is H or methyl and R_3 is methyl.

6. A compound of claim 4 wherein n is 1.

7. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of formula I according to claim 1.

8. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of formula II according to claim 4,.

9. A pharmaceutical composition according to claim 7 for treating a proliferative disease.

10. A pharmaceutical composition according to claim 8 for treating a proliferative disease.

11. A method of treating a proliferative disease which comprises administering a therapeutically effective amount of a compound of formula I according to claim 1 to a mammal in need of such treatment.

10. A method of treating a proliferative disease which comprises administering a therapeutically effective amount of a compound of formula II according to claim 4 to a mammal in need of such treatment.

11. A method of claim 11 wherein the mammal is a human.

12. A method of claim 12 wherein the mammal is a human.

13. Use of a compound of formula I according to claim 1 for the manufacture of a medicament for treating a proliferative disease.

14. Use of a compound of formula II according to claim 4 for the manufacture of a medicament for treating a proliferative disease.